Preparing for thalidomide's comeback.
Vanchieri
C
C
D017277:Drug Approval; D004893:Erythema Nodosum / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D008297:Male; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D007917:Leprostatic Agents; D013792:Thalidomide